

GLAXOSMITHKLINE PLC

Form 6-K

July 21, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 21 July 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No ☒

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr N Hirons
 - b) Position/status SVP, Global Ethics & Compliance
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument

GlaxoSmithKline plc
American Depositary Shares ('ADSs')

ISIN: US37733W1053
 - b) Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 13 July 2017.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
\$42.8125	16.250

Aggregated information
 - d) n/a (single transaction)
 - e) Aggregated volume Price
 - f) Date of the transaction 2017-07-20
 - Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr B McNamara
 - b) Position/status CEO, Consumer Healthcare
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

American Depositary Shares
(‘ADSs’)

a) Description of the financial instrument

ISIN: US37733W1053

b) Nature of the transaction

Acquisition of ADSs
following the re-investment
of dividends paid to
shareholders on 13 July 2017.

c) Price(s) and
volume(s)

Price(s)	Volume(s)
\$42.8125	192.536

Aggregated information

n/a (single transaction)

d)

Aggregated volume Price

e) Date of the transaction

2017-07-20

f) Place of the transaction

New York Stock Exchange
(XNYS)

1. Details of PDMR/person closely associated with them (‘PCA’)

a) Name

Mr D E Troy

b) Position/status

SVP & General Counsel

c) Initial notification/
amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

American Depositary Shares
(‘ADSs’)

a) Description of the financial instrument

ISIN: US37733W1053

b) Nature of the transaction

Acquisition of ADSs
following the re-investment
of dividends paid to
shareholders on 13 July 2017.

c) Price(s) and
volume(s)

Price(s)	Volume(s)
\$42.8125	1,512.409

Aggregated information

n/a (single transaction)

d)

Aggregated volume Price

e) Date of the transaction

2017-07-20

f) Place of the transaction

New York Stock Exchange
(XNYS)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: July 21, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc